ml390

ml390 Suppliers list
Company Name: BOC Sciences
Tel: +1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:ML390
CAS:2029049-79-2
Purity:99% Package:100mg Remarks:BOC Sciences also provides custom synthesis services for ML390.
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:ML390
CAS:2029049-79-2
Purity:98.00% Package:10 mg;100 mg;5 mg;50 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: InvivoChem
Tel: +1-708-310-1919 +1-13798911105
Email: sales@invivochem.cn
Products Intro: Product Name:ML390
CAS:2029049-79-2
Purity:98% Package:5mg Remarks:V2626
Company Name: Aladdin Scientific
Tel: +1-833-552-7181
Email: sales@aladdinsci.com
Products Intro: Product Name:ML390
CAS:2029049-79-2
Purity:99% Package:$68.9/5mg;$88.9/10mg;$200.9/25mg;$226.9/50mg;$404.9/100mg;Bulk package Remarks:99%
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 021-13816613772 13816613772
Email: huahero21@sina.com
Products Intro: Product Name:ml390
Purity:98% Package:10mg,100mg,1g
ml390 Basic information
Product Name:ml390
Synonyms:ml390;Benzamide, N-[3-oxo-3-[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]propyl]-4-(trifluoromethoxy)-;ER-HoxA9,Dihydroorotate Dehydrogenase,inhibit,AML,ML 390,differentiatio,U937,DHODH,ML390,myeloid,ML-390,Inhibitor,THP1;(R)-N-(3-Oxo-3-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)propyl)-4-(trifluoromethoxy)benzamide
CAS:2029049-79-2
MF:C21H21F3N2O3
MW:406.4
EINECS:
Product Categories:
Mol File:2029049-79-2.mol
ml390 Structure
ml390 Chemical Properties
Boiling point 599.7±50.0 °C(Predicted)
density 1.31±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility ≥40.6 mg/mL in DMSO; insoluble in H2O; ≥17.47 mg/mL in EtOH
form solid
pka13.65±0.46(Predicted)
Safety Information
MSDS Information
ml390 Usage And Synthesis
DescriptionML-390 is an inhibitor of dihydroorotate dehydrogenase (DHODH), the enzyme that converts dihydroorotate to orotate during de novo pyrimidine synthesis. In acute myeloid leukemia, leukemic myeloblast development is halted at an immature stage leading to perpetual self-renewal rather than differentiation. ML-390 induces differentiation in the acute myeloid leukemia cell lines U937 (murine) and THP-1 (human) cell lines with an EC50 value of approximately 2 μM.
in vitroin the screening study, ml390 was identified as the most potent compound against the engineered erhox-gfp cell line. moreover, the addition of uridine to the cell culture media could abrogate the differentiation effects of ml390, demonstrating further evidences that ml390’ effects were due to their inhibition of dhodh-catalyzed pyrimidine synthesis. in addition, ml390 was found to be not able to inhibit dhodh in the p. falciparum parasite, which is the causative agent of malaria. furthermore, the x-ray structure indicated that the binding of ml390 to the enzyme might be increased by modifying ml390 with a ring in its central portion to lock the molecule into its binding conformation with the amide substituents [1].
IC 500.56 μm
references[1] timothy a lewis et al. development of ml390: a human dhodh inhibitor that induces differentiation in acute myeloid leukemia. acs med chem lett 2016 dec 28;7(12):1112-1117. epub 2016 sep 28.
ml390 Preparation Products And Raw materials
Tag:ml390(2029049-79-2) Related Product Information
ML385 ML365 ML 141 ML355 M348 (2,4,6-Trichloro-phenoxy)-acetic acid (1H-pyrrol-2-ylmethylene)-hydrazide 5-[(4-Nitrobenzoyl)oxy]-2-[(2-pyrimidinylthio)methyl]-4H-pyran-4-one ML277 ML364 VU0456810 ML-327